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Cdc25 regulates entry into mitosis by regulating the
activation of cyclin B/cdc2. In humans, at least two
cdc25 isoforms have roles in controlling the G2/M tran-
sition. Here we show, using bacterially expressed re-
combinant proteins, that two cdc25B splice variants,
cdc25B2 and cdc25B3, are capable of activating cyclin
A/cdk2 and cyclin B/cdc2, but that mitotic hyperphos-
phorylation of these proteins increases their activity
toward only cyclin B1/cdc2. Cdc25C has only very low
activity in its unphosphorylated form, and following hy-
perphosphorylation it will efficiently catalyze the acti-
vation of only cyclin B/cdc2. This was reflected by the in
vivo activity of the immunoprecipitated cdc25B and
cdc25C from interphase and mitotic HeLa cells. The in-
creased activity of the hyperphosphorylated cdc25s to-
ward cyclin B1/cdc2 was in large part due to increased
binding of this substrate. The substrate specificity, ac-
tivities, and timing of the hyperphosphorylation of
cdc25B and cdc25C during G2 and M suggest that these
two mitotic cdc25 isoforms are activated by different
kinases and perform different functions during progres-
sion through G2 into mitosis.
Regulation of the activity of cyclin-dependent kinases (cdks)1
underlies cell cycle progression. Cdks are regulated by a com-
bination of factors, including cyclin association, and phospho-
rylations and dephosphorylations of the cdk subunit. The final
step in the activation of cyclin/cdks is catalyzed by a member of
the cdc25 family of dual specificity phosphatases, which re-
move inhibitory phosphates from Thr14 and Tyr15 of cdk2 and
cdc2.
The role and regulation of cdc25 phosphatase has been well
defined in yeast and Xenopus egg systems, using a combination
of genetics and biochemistry. In Schizosaccharomyces pombe,
cdc25 is controlled at the transcriptional, translational, and
post-translational levels. The mRNA and protein levels oscil-
late through the cell cycle, being maximal in G2, but the protein
requires further post-translational modification in the form of
phosphorylation for maximal activity (1, 2). Xenopus cdc25
levels do not change, but its activity is also controlled by phos-
phorylation and dephosphorylation (3, 4). In humans, three
isoforms of cdc25 exist, cdc25A, -B, and -C. Cdc25A has a role
in regulating the G1/S cell cycle phase transition whereas
cdc25B and cdc25C regulated the G2/M transition (5–9). The
level of mRNA for each isoform changes through the cell cycle,
but the protein levels of only cdc25A and cdc25B have been
reported to change in a cell cycle-dependent manner (5, 7, 9).
All three cdc25s are phosphorylated in vivo, and phosphoryla-
tion has been demonstrated to regulate the activity of cdc25A
and cdc25C (6, 10, 11).
Whereas the in vivo substrates identified for the cdc25s to
date are the Tyr-phosphorylated cyclin/cdks, cdc25 activity has
usually been measured in vitro using a range of substrates,
most of which are non-physiological e.g. p-nitrophenyl phos-
phate. The cdc25 phosphatases utilize this substrate very
poorly (12), and there is evidence that the cyclin subunit of the
cdk complexes directly modifies the activity of cdc25 (13, 14), a
subtlety which would be lost with the artificial substrates.
While different cdc25 isoforms have been demonstrated to ac-
tivate a range of different cyclin/cdks (15–17), there are no data
on the relative activity of the cdc25 isoforms toward the differ-
ent cyclin/cdks, nor data on how the observed phosphorylations
of the different cdc25 isoforms affects their activities toward
the cyclin/cdk substrates.
In this report, we provide biochemical evidence that two
cdc25B splicing variants and cdc25C utilize cyclin A/cdk2 and
cyclin B1/cdc2 as substrates with different efficiencies. Using
bacterially expressed GST fusion proteins of cdc25B, cdc25C,
and catalytic domain constructs, we demonstrate that in vitro
two cdc25B splicing variants identified (18)2 have relatively
high activity toward both cyclin A/cdk2 and cyclin B1/cdc2,
whereas cdc25C will activate cyclin B1/cdc2 to the same extent
as the cdc25Bs only after hyperphosphorylation. The phospho-
rylation induced increases in activity of all the cdc25s are due
to increased binding of the cyclin/cdks. Similar increases in
activity were observed for the hyperphosphorylated forms of
cdc25B and cdc25C immunoprecipitated from mitotic HeLa
cells. Activity assays of chimeric constructs of cdc25B and
cdc25C revealed that exchanging the N-terminal regulatory
domains significantly modified their catalytic activities. We
propose that mitotic hyperphosphorylation modifies the struc-
ture of the N-terminal regulatory domain of the cdc25s to allow
better access of cyclin/cdk to the catalytic domain.
MATERIALS AND METHODS
Cell Culture and Synchrony—HeLa cells were cultured in RPMI 1640
with 5% bovine serum (Serum Supreme, Biowhittaker). Single and
double thymidine block/release synchronies of HeLa cultures were per-
formed as described previously (19).
Production and Expression of GST-cdc25s—Production of GST fusion
proteins of wild type and catalytically inactive C/S and CR/SK mutants
of cdc25B3 (using the nomenclature of Baldin et al. (18)) and cdc25C,
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where critical Cys and Arg residues have been mutated to Ser and Lys,
are described elsewhere (9, 20), and production of GST-cdc25B2 is
described elsewhere.2 The cdc25 chimeras were produced by cutting
full-length cdc25B3 and cdc25C in pUCSRa (9) with AvrII, which cuts
the vector 59 of the cloned cDNAs and both cdc25s in the N-terminal
regulatory domains. The excised AvrII/AvrII fragments from each cdc25
were then subcloned into the corresponding sites of the other cdc25. The
fragments were ligated in-frame and encoded chimeric cdc25s from
cdc25B3 codon 1–251 and cdc25C 181–472 (designated cdc25BC2), and
cdc25C codon 1–180 and cdc25B3 252–580 (designated cdc25CB3). The
chimeras were then subcloned in pGEX 2T (Pharmacia) as either an
XbaI/XbaI fragment of cdc25BC2 into the XbaI-digested pGEX-cdc25B3
(9), or BamHI/BamHI fragment of cdc25CB3 subcloned in BamHI di-
gested pGEX 2T. The production of GST fusion proteins of the C-
terminal fragments of both cdc25B3 and cdc25C has been described
elsewhere (20).2 The GST fusion proteins were expressed in Escherichia
coli DH5a and the induced proteins were extracted by Sarkosyl lysis
and affinity purified on glutathione-agarose as described previously (9),
modified to include 5 mM DTT in all extraction and washing buffers.
Cdc25 Activity Assays—The activity of the GST-cdc25 fusion proteins
was assayed by their ability to activate the Tyr15-phosphorylated forms
of cyclin B1/cdc2 or cyclin A/cdk2. The cdc25 activity was quantitated as
the increased histone H1 kinase activity of the activated cyclin/cdk. The
cyclin/cdks were isolated by immunoprecipitation with either anti-cy-
clin B1 antibody (9) from extracts of HeLa cells harvested 8 h after
release from an overnight block in 2.5 mM thymidine (when the cells are
in late S or early G2 phase, S/G2), or an anti-cdk2 polyclonal (Santa
Cruz) or anti-cyclin A monoclonal (Pharmingen) antibody from over-
night thymidine-blocked HeLa cells (G1/S). The cell lysates were pre-
pared and immunoprecipitations performed as described previously (9).
Affinity purified GST-cdc25s were eluted from glutathione-agarose with
10 mM reduced glutathione in phosphatase buffer (20 mM TriszHCl, 2
mM EDTA, 5 mM DTT, 150 mM NaCl, 0.1% Triton X-100, pH 8.3)
supplemented with 0.1 mg/ml bovine serum albumin. The amount of
GST-cdc25 eluted was quantitated by laser densitometry of Coomassie
Blue-stained bands of the full-length fusion proteins in 30-ml aliquots
resolved on a 10% SDS-PAGE gel (Fig. 1B), using bovine serum albumin
as a standard. The eluted GST-cdc25s (30 ml) were added to immuno-
precipitates of either cyclin B1/cdc2 or cyclin A/cdk2, and incubated for
20 min at 30 °C. The reaction was stopped by addition of 5 ml of 5 mM
sodium vanadate, and the histone H1 kinase activity assayed as de-
scribed previously (9). The level of histone phosphorylation was quan-
titated by PhosphorImaging and the cdc25 activity expressed as fold
increase in histone kinase activity over the control, normally the cata-
lytically inactive GST-cdc25B3 CR/SK mutant. Where indicated, the
eluted GST-cdc25s were diluted with elution buffer. In all assays,
GST-cdc25CB3 was initially diluted 3-fold to give a similar level of
protein as that of the eluted GST-cdc25Bs and GST-cdc25C.
The activity of HeLa cell cdc25B and cdc25C was assayed by immu-
noprecipitation from extracts of either G1/S or S/G2 synchronized cells,
or mitotic cells (M) obtained by mitotic shake-off of cells arrested in M
phase with nocodazole (0.2 mg/ml) 14 h after release from a thymidine
block. Cells were lysed in NETN (20 mM TriszHCl, 1 mM EDTA, 100 mM
NaCl, 0.5% Nonidet P-40, pH 8) supplemented with 0.3 M NaCl, 5 mM
DTT, 5 mg/ml leupeptin, aprotinin, and pepstatin, and 0.5 mM phenyl-
methylsulfonyl fluoride, and the phosphatase inhibitors 0.1 mM sodium
vanadate, 10 mM sodium fluoride, 2 mM microcystin, and 20 mM can-
tharidin. The lysates were precleared with 30 ml of a 50% suspension of
protein A-Sepharose for 30 min then the cdc25s were immunoprecipi-
tated by addition of 0.1–0.5 mg of either affinity purified cdc25B or
cdc25C specific antibody (9) and 30 ml of 50% protein A-Sepharose. The
antibody was incubated with the lysate for 3 h at 4 °C, then the pre-
cipitates washed as for the glutathione-agarose precipitates with NETN
supplemented with 5 mM DTT. Finally, the precipitates were washed
once with phosphatase buffer into fresh tubes, and the cdc25 activity
assayed by the activation of a Thr14/Tyr15 and Thr161-phosphorylated
cdc2-cyclin B1 complex (PY15) produced in vitro. Briefly, baculovirus-
expressed human cyclin B1 GST fusion protein was bound to glutathi-
one-agarose, then incubated in a HeLa cell lysate with the addition of 2
mM ATP, 15 mM MgCl2, and the cdk inhibitor olomoucine (0.1 mM). The
agarose bound GST-cyclin B1/cdc2 was washed and cleaved from the
GST moiety with thrombin. The released Thr14, Tyr15, and Thr161-
phosphorylated cdc2/cyclin B1 was then stored at 270 °C until use. 5 ml
of PY15 substrate was diluted with 15 ml of phosphatase buffer and
incubated with the immunoprecipitated cdc25 for 30 min at 30 °C. The
reaction was stopped by addition of 5 ml of 5 mM sodium vanadate, and
the increase in H1 kinase activity measured as described above. Cdc25
activity was quantitated as the increased histone kinase activity of the
substrate. The controls in these experiments were preimmune IgG
immunoprecipitates from M phase samples, although preimmune con-
trol values from each cell cycle sample were the same.
In Vitro Phosphorylation and Dephosphorylation of Cdc25—In vitro
phosphorylation of the GST-cdc25s was performed using extracts of
mitotic HeLa cells obtained from mitotic shake-off of overnight nocoda-
zole-blocked HeLa cultures. The cells were lysed in 50 mM TriszHCl, 5
mM EDTA, 250 mM NaCl, 5 mM DTT, 0.1% Triton X-100 with protease
and phosphatase inhibitors as above, except that the vanadate concen-
tration was increased to 0.3 mM and microcystin to 5 mM. The lysate was
precleared by incubation with 0.4 ml of a 50% suspension of glutathi-
one-agarose for 1 h, then 2–4 mg of lysate was added to GST-cdc25s
bound to glutathione-agarose. The GST-cdc25s were incubated with the
lysates either with or without addition of 2 mM ATP and 15 mM MgCl2
for 15 min at 30 °C, then supplemented with a further 1 mM ATP and
incubated a further 15 min. The glutathione-agarose bound GST-cdc25s
were then washed, eluted, and assayed as described above. In some
cases, the phosphorylated cdc25s were dephosphorylated prior to elu-
tion using 1 unit of l-phosphatase (New England Biolabs) for 30 min at
30 °C as per the manufacturer’s conditions. The degree of phosphoryl-
ation was assessed by electrophoresis of the eluted GST-cdc25s on 10%
SDS-PAGE, and immunoblotting the resolved proteins with an anti-
GST antibody. The phosphorylated cdc25s migrated as lower mobility
species (9, 10).
Cdc25-associated Cyclin/Cdks—Molt4 cells harvested 8 h after re-
lease from a thymidine block (predominantly S/G2 phase cells), were
lysed in NETN supplemented with 0.3 M NaCl, 5 mg/ml leupeptin,
pepstatin, and aprotinin, 0.5 mM phenylmethylsulfonyl fluoride, 0.2 mM
sodium vanadate, and 20 mM sodium fluoride, and precleared with
glutathione-agarose for 1 h at 4 °C. GST-cdc25 C/S mutants bound to
glutathione-agarose was incubated in 1.25 mg of lysate at 0.5 mg/ml
protein for 2 h at 4 °C, the bead pellets washed 4 times with NETN, and
the bound protein eluted by boiling in 2 3 SDS sample buffer. The
eluted proteins were analyzed by immunoblotting with either anti-cdc2
(Santa Cruz) monoclonal antibody, anti-GST, or anti-cdk2 (Santa Cruz)
affinity purified polyclonal antibodies, using ECL detection.
p-Nitrophenylphosphatase Assays—p-Nitrophenyl phosphate (30
mM) in phosphatase buffer was added to 60 ml of eluted GST-cdc25 to
give a final volume of 200 ml, and incubated at 30 °C for 1 h. The
reaction was stopped by the addition of 300 ml of 2 M NaOH and the
turnover of p-nitrophenyl phosphate determined as the increased ab-
sorbance at 410 nm using the e of 18,000 M21 cm21 for p-nitrophenol.
RESULTS
Production of cdc25B and cdc25C Chimeras—To investigate
the intrinsic activities of the two splicing variants of cdc25B
and cdc25C, GST fusion proteins of each were expressed in
bacteria and purified by glutathione-agarose affinity chroma-
tography. These proteins have previously been shown to be
active as phosphatases in vitro, using a number of different
substrates (9, 15, 20). A series of chimeric proteins were also
produced, where the conserved N-terminal regions of the
cdc25B3 variant and cdc25C were exchanged (Fig. 1A). Ex-
change of the N-terminal regions was expected to change the
regulation and possibly substrate specificity of chimeric cata-
lytic subunit, but not change its catalytic properties signifi-
cantly. Full-length GST fusion proteins were expressed and
purified for each of the cdc25s, C-terminal constructs and two
chimeric proteins, but we were unable to purify a full-length
version of another chimeric cdc25, cdc25BC1 (Fig. 1B).
The activity of the GST-cdc25s was initially assayed using
p-nitrophenyl phosphate as substrate. The catalytic C-terminal
regions of the two cdc25Bs and cdc25C display a high degree of
sequence identity and would thus be expected to have similar
catalytic properties. When the activities of the GST-cdc25s
were compared on an equimolar basis, cdc25B C-terminal frag-
ment construct was found to have a 4–5-fold greater activity
than either cdc25B variant, which had similar activities with
p-nitrophenyl phosphate (Table I). The full-length cdc25C and
its isolated C-terminal domain construct had similar activity
with this substrate, although this was less than half the activ-
ity of the cdc25Bs. Interestingly, the two full-length chimeras
had very different p-nitrophenylphosphatase activities from
Hyperphosphorylation of the N-terminal Domain of Cdc2528608
 at UQ Library on October 19, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
their parent forms, cdc25BC2 was essentially inactive with this
substrate, whereas cdc25CB3 had 3-fold higher activity than
cdc25B3, but a similar activity to the cdc25B C-terminal frag-
ments (Table I).
The activity of the GST-cdc25Bs and GST-cdc25C with p-
nitrophenyl phosphate indicated only small differences be-
tween the catalytic activities of the bacterially expressed pro-
teins. Others have shown that the cyclin subunit of the in vivo
substrates of cdc25, the cyclin/cdks, can contribute to the ac-
tivity and possibly specificity of the cdc25 (13, 14). To investi-
gate this possibility, the activity of the GST-cdc25s, chimeras,
and C-terminal constructs toward Thr14/Tyr15-phosphorylated
cdc2/cyclin B1 isolated from S/G2 HeLa cells and Tyr
15-phos-
phorylated cdk2/cyclin A isolated from G1/S HeLa cells was
assayed. The activity of each GST-cdc25 was assayed as a
dilution series to account for the differences in the levels of
each GST fusion protein expressed in bacteria, and their dif-
ferent relative activities. Cdc25 activity was measured by the
activation of immunoprecipitated, Tyr15-phosphorylated cyclin/
cdk, and quantitated in terms of the increased histone kinase
activity of the complexes (Fig. 2A).
Cdc25B C-terminal fragments and chimeric cdc25CB3 had
the highest relative activities toward both cyclin B1/cdc2 and
cyclin A/cdk2 (Fig. 2, B and C). Cdc25B2 and cdc25B3 had
similar levels of activity toward cyclin B1/cdc2, but cdc25B2
displayed a 2–4-fold higher activity toward cyclin A/cdk2 than
FIG. 1. A, schematic diagram of the GST-cdc25s and chimeras used. The restriction sites used to construct the chimeras and C-terminal domains,
and the codons at which they cut are indicated. The conserved catalytic domain of cdc25B3 and cdc25C, cdc25B3[385–581] and cdc25C[275–473],
are shown as differently shaded regions. B, Coomassie Blue-stained SDS-PAGE gel of eluted GST-cdc25s and chimeras used. The strongly staining
bands less than 36 kDa are premature termination products of the GST fusion proteins. The minor bands migrating between these and the
full-length proteins are truncations in the C-terminal catalytic domain and therefore inactive.
TABLE I
p-Nitrophenylphosphatase activity of the GST-cdc25s
The activity of each GST-cdc25 was calculated from five separate
experiments, and calculated as described under “Materials and
Methods.”
Activity
mM/min/mg
Cdc25B2 59
Cdc25B3 74
Cdc25C 25
Cdc25BC2 ,1
Cdc25CB3 237
Cdc25B C-terminal 350
Cdc25C C-terminal 26
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cdc25B3. Neither GST-cdc25C, cdc25C C-terminal fragments,
nor chimeric cdc25BC2 displayed significant activity toward
cyclin A/cdk2, although GST-cdc25C and GST-cdc25C C-termi-
nal fragments activated cyclin B1/cdc2 2–3-fold. The difference
in the relative activities of the GST-cdc25s toward p-nitrophe-
nyl phosphate and the immunoprecipitated cyclin/cdks was not
a consequence of steric interference of the GST moiety, as
removal of the GST moiety with thrombin followed by assay
using p-nitrophenyl phosphate or immunoprecipitated cyclin
B1/cdc2 gave similar relative activities (data not shown).
Mitotic Phosphorylation and Activation of the GST-Cdc25s—
Mitotic hyperphosphorylation of cdc25C is associated with its
increased activity using a number of non-physiological sub-
strates (10, 11), and phosphorylation of cdc25B is correlated
with its activity in vivo (9). To test the effects of mitotic hyper-
phosphorylation on cdc25 activity toward cyclin A/cdk2 and
cyclin B1/cdc2, the full-length GST-cdc25s and chimeras were
phosphorylated in vitro using extracts from mitotic HeLa cells.
The phosphorylated cdc25s displayed the characteristically re-
tarded electrophoretic mobilities observed for these proteins in
vivo (Fig. 3A; Refs. 9 and 10). In these experiments, all of the
GST-cdc25C was shifted to the hyperphosphorylated form as
was cdc25CB3, whereas only half of the cdc25B2, cdc25B3, and
cdc25BC2 was in the retarded form. The phosphorylated GST-
cdc25s were assayed for their activity toward immunoprecipi-
tated S/G2 cyclin B1/cdc2 (Fig. 3B). Hyperphosphorylation of
GST-cdc25B2 and cdc25B3 resulted in 2–3-fold and 3–5-fold
activation, respectively. Chimeric GST-cdc25BC2 again
showed no activity after mitotic phosphorylation, although
phosphorylation of the cdc25B3 N-terminal regulatory domain
produced a similar change in electrophoretic mobility to that
seen in the full-length cdc25Bs (Fig. 3A). GST-cdc25CB3
showed a small increase in activity (no more than 2-fold),
whereas phosphorylation of GST-cdc25C produced the greatest
increase in activity, to have greater cdc25 activity on a relative
mole cdc25 basis than either of the activated cdc25Bs, although
this was still less than the activated GST-cdc25CB3 (Fig. 3B,
lower panel). The increased histone kinase activity was not due
to any histone kinase associated with the phosphorylated GST-
cdc25s from the HeLa extracts used for phosphorylation, as no
increase in histone kinase activity was associated with mitotic
phosphorylation of the catalytically inactive GST-cdc25B3
CR/SK mutant, which was used as the control for this experi-
ment or with GST-cdc25BC2.
To determine whether the mitotic phosphorylation of the
FIG. 2. Relative activities of the GST-cdc25s. A, the activity of
each GST-cdc25 was measured using serial dilutions of the eluted
proteins, with the inactive GST-cdc25B3 CR/SK mutant as a control.
The GST-cdc25s were incubated with immunoprecipitated Thr14/Tyr15-
phosphorylated cyclin B1/cdc2 or cyclin A/cdk2 and the increased his-
tone H1 kinase activity was quantified as a measure of the relative
cdc25 activities. The dilution series for GST-cdc25B2 is shown with the
undiluted, inactive GST-cdc25B3 CR/SK mutant control. The top half of
the gel was immunoblotted for cdc25B (acdc25B), and the cdc25 activity
quantified as increased histone H1 kinase activity (H1K) of the acti-
vated cyclin B1/cdc2 immunoprecipitate on the lower half. B and C, the
activity of GST-cdc25B C-terminal (solid circles), cdc25CB3 (solid
squares), cdc25B2 (solid diamonds), cdc25B3 (open squares), cdc25C
(solid triangles), cdc25BC2 (open diamonds), and cdc25C C-terminal
(open circles) were assayed for activation of cyclin B1/cdc2 (B) and cyclin
A/cdk2 (C). The amount of cdc25 in each assay is expressed as the
number of moles of cdc25 relative to the number of moles of GST-
cdc25B3 in the undiluted sample, which has been normalized to 1 mol.
Cdc25 activity is expressed as fold increase in histone kinase activity
over the control incubation with catalytically inactive GST-cdc25B3
CR/SK mutant.
FIG. 3. Hyperphosphorylation of GST-cdc25s by mitotic ki-
nases increases their activity. A, GST-cdc25s were incubated in
mitotic HeLa cell extracts either with or without the addition of Mg/
ATP. The hyperphosphorylated forms of the GST-cdc25s are visible as
the slower mobility bands detected with an anti-GST antibody (aGST).
B, the cdc25 activity of the hyperphosphorylated and unphosphorylated
GST-cdc25s were measured as described in the legend for Fig. 2. The
hyperphosphorylated GST-cdc25s are shown as solid symbols and their
corresponding unphosphorylated controls are the open symbols.
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GST-cdc25s was directly responsible for the increased activities
observed, the GST-cdc25s were phosphorylated as in the pre-
vious experiment, then incubated either with or without recom-
binant l-phosphatase to dephosphorylate the proteins, follow-
ing which the phosphatase was washed away and the GST-
cdc25s assayed for activity using immunoprecipitated S/G2
cyclin B1/cdc2 and G1/S cyclin A/cdk2 as substrates. The l-
phosphatase completely dephosphorylated the GST-cdc25s in
each case (Fig. 4A). Interestingly, the hyperphosphorylated
GST-cdc25C was poorly stained with the anti-GST antibody,
which was also seen using anti-cdc25C antibody (data not
shown). The differences in the activity levels of the phospho
and dephospho-forms of the GST-cdc25s for cyclin B1/cdc2 (Fig.
4B) were similar to those seen with the phosphorylated and
unphosphorylated GST-cdc25s in the previous experiment (Fig.
3B). Surprisingly, the mitotic phosphorylation of the GST-
cdc25s had little effect on their activity toward the immuno-
precipitated cyclin A/cdk2 (Fig. 4B, lower panel). The low de-
gree of cdc25 activation in the experiment shown was due to the
relatively high histone kinase activity of the immunoprecipi-
tated cyclin A/cdk2. Despite this high background, GST-
cdc25CB3 produced a 5-fold activation, indicating that the lack
of hyperphosphorylation induced increase in activity of the
GST-cdc25s similar to that seen with cyclin B1/cdc2 was not
due to an insensitive cyclin A/cdk2 substrate. In this experi-
ment, anti-cdk2 immunoprecipitates were used, but a similar
lack of phosphorylation dependent activation was observed
using anti-cyclin A immunoprecipitates (data not shown). The
small increase in GST-cdc25B3 activity with cyclin A/cdk2 was
consistently observed.
The mechanism by which the mitotic phosphorylation in-
creased the activity of cdc25B and cdc25C was further investi-
gated, taking advantage of the ability of the catalytically inac-
tive cdc25 C/S mutants to form stable complexes with the
substrate cdk-cyclin complexes (21). The C/S mutants of GST-
cdc25B2, cdc25B3, and cdc25C were hyperphosphorylated with
mitotic HeLa extracts as in the previous experiments, and were
used to pull down interacting cdk/cyclins from extracts of syn-
chronized S/G2 Molt4 cells. The binding of cdk2 and cdc2 com-
plexes was analyzed by immunoblotting, compared with the
unphosphorylated GST-cdc25s as controls. The levels of hyper-
phosphorylation obtained were equivalent to those obtained in
the earlier phosphorylation experiments (Fig. 5). GST-cdc25B2
C/S mutant bound a high level of cdk2 compared with the other
GST-cdc25 C/S mutants, with no phosphorylation-dependent
increase, whereas GST-cdc25B3 C/S displayed a small, 1.5–3-
fold increase in cdk2 binding with phosphorylation, and GST-
cdc25C C/S bound only very low levels of cdk2. By contrast, all
GST-cdc25 C/S mutants displayed significant phosphorylation
dependent increases in cdc2 complex binding, with cdc25B2
having a 2–4-fold increase, while GST-cdc25B3 and GST-
cdc25C displayed a 5–10-fold increase in cdc2 association; the
smaller phosphorylation dependent increase with GST-
cdc25B2 was related to the higher levels of cdc2 bound by its
unphosphorylated form (Fig. 5).
Activity of Interphase and Mitotically Phosphorylated Cdc25s
in Vivo—Measurement of the in vitro activity and activation of
the GST-cdc25s provides a useful indicator of the intrinsic
activities of the unmodified recombinant proteins, and the ef-
fect of mitotic phosphorylation. However, other factors apart
from the phosphorylation status of these proteins may effect
their activities. To test whether this was the case, the activities
of the immunoprecipitated cdc25B and cdc25C from synchro-
nized HeLa cell cultures were measured using a soluble Thr14/
Tyr15-phosphorylated cdc2/cyclin B1 (PY15) produced in vitro.
Immunoprecipitated cdc25B (this included both cdc25B2 and
cdc25B3) was active in S/G2 HeLa cell samples, but the mitot-
ically phosphorylated cdc25B was further activated, in this
case 2-fold (Fig. 6A). In these experiments only half of the
cdc25B was in the electrophoretically retarded form, suggest-
ing that hyperphosphorylation of the entire complement of
cdc25B would produce at least a 4-fold increase in activity.
Dephosphorylation of the hyperphosphorylated form using l-
phosphatase resulted in the loss of the slower mobility form of
the protein and reduction of its activity, although this was still
higher than S/G2 levels (Fig. 6B). Immunoprecipitated cdc25C
was found to have a very low level of activity in G1/S phase cell
samples, and S/G2 samples showed only a small but reproduc-
ible increase in activity, although this was much less than the
activity of the mitotic samples (Fig. 6C), which mirrored the
.10-fold increased activity observed in vitro (Fig. 4B). Dephos-
phorylation of the hyperphosphorylated cdc25C resulted in the
loss of the retarded mobility form of the protein and reduction
of cdc25C activity to G1/S phase levels (Fig. 6D), as shown by
others (10, 11). This supports the model for the mitotic activa-
tion of cdc25C being through its mitotic hyperphosphorylation.
However, the inability of l-phosphatase to reduce cdc25B ac-
tivity to S/G2 levels, even though it did completely convert
cdc25B to the more rapidly migrating form, suggests that other
factors in addition to phosphorylation may be involved in the
mitotic activation of cdc25B.
The different substrate specificities and enzyme activities
through the cell cycle suggested that cdc25B and cdc25C may
FIG. 4. Hyperphosphorylation of the GST-cdc25s increased
their activity with cyclin B1/cdc2 but not cyclin A/cdk2. A, GST-
cdc25s were hyperphosphorylated as described in the legend to Fig. 3,
and then incubated either with or without l-phosphatase (l). The
dephosphorylation was detected as an increase in the electrophoretic
mobility of the bands immunoblotted with anti-GST antibody. B, the
activity of the hyperphosphorylated and dephosphorylated GST-cdc25s
in A shown as histone kinase activity and quantified as fold increase
over the CR/SK control, with either immunoprecipitated cyclin B1/cdc2
or cyclin A/cdk2 as substrate.
FIG. 5. Hyperphosphorylation increases the affinity for cdc2
but not cdk2-cyclin complexes. GST-cdc25 C/S mutants were hyper-
phosphorylated as in Fig. 3, incubated in extracts of Molt4 cells syn-
chronized in late S/G2 phase, and the levels of bound cdc2 and cdk2-
cyclin complexes assessed by immunoblotting for these proteins. The
relative levels of GST-cdc25s are indicated in the GST immunoblot.
Lysates of asynchronously growing HeLa cells were also run as controls
for the immunoblotted cdc2 and cdk2. The strongly staining band run-
ning ahead of the cdk2 doublet is a cross-reactive species.
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regulate the activation of different pools of mitotic cyclin/cdks.
This was further supported by the timing and proportion of the
cdc25B and cdc25C activated during the cell cycle. Immuno-
blotting of HeLa cells synchronized using a double thymidine
block/release protocol, which resulted in up to 80% of cells
progressing synchronously from early S phase through to mi-
tosis, revealed hyperphosphorylated forms of cdc25B as early
as 8 h after release, when cells were in late S/early G2 phase,
preceded the activation of cyclin B1/cdc2 (Fig. 7). In contrast,
the hyperphosphorylated form of cdc25C was only detected at
10 h simultaneous with the activation of cyclin B1/cdc2. The
hyperphosphorylated form accounted for only a small propor-
tion of the total cdc25C. This low proportion is clearly indicated
by the apparently similar levels of the underphosphorylated
cdc25C in all the time point samples, and cannot be accounted
for by incomplete synchrony of the cultures, loss due to dephos-
phorylation in the extract as the majority of the cdc25B is
present in hyperphosphorylated form at 10 h after release (Fig.
7), or the reduced sensitivity of immunoblotting for the hyper-
phosphorylated form already noted with the in vitro hyper-
phosphorylated cdc25C (Figs. 4A and 5).
DISCUSSION
The in vitro analysis of cdc25 substrate specificity and acti-
vation reported here has provided a biochemical basis for the
observed activities of cdc25B and cdc25C in vivo. The catalytic
properties of the isolated catalytic domains of these two phos-
phatases were surprisingly different considering they share
over 56% identity and 67% homology of the amino acid se-
quences in the conserved catalytic domains. The cdc25B C-
terminal had the highest activity of all the GST-cdc25s with all
of the substrates used, whereas cdc25C C-terminal fragments
dephosphorylated p-nitrophenyl phosphate and cyclin B1/cdc2
at only 10% the rate of cdc25B C-terminal fragments and was
essentially inactive with cyclin A/cdk2 (Table II). This suggests
that some of the differences in activities of the full-length
cdc25s is due to the different activities of the catalytic domains.
Interestingly, full-length cdc25C and its C-terminal domain
construct had similar activities toward p-nitrophenyl phos-
phate, consistent with a previous report (20), and the cyclin/
cdks, whereas cdc25B2 and cdc25B3 had only 25% the activity
of their common catalytic domain construct with all the sub-
strates tested here (Table II). The difference in the catalytic
activities of cdc25B2 and similar C-terminal constructs has
also been observed by others using p-nitrophenyl phosphate as
a substrate (21).
The relative ability of the bacterially expressed GST-cdc25s
to bind cyclin A/cdk2 and cyclin B1/cdc2 generally reflected the
relative catalytic rates of the GST-cdc25s with cyclin A/cdk2
and cyclin B1/cdc2.2 Hyperphosphorylation of the GST-cdc25s
resulted in increased binding of cyclin B1/cdc2, which would
FIG. 6. In vivo activity of cdc25B and cdc25C through the cell
cycle. Immunoprecipitated cdc25B and cdc25C were assayed using the
soluble PY15 substrate (see “Materials and Methods”). The immuno-
precipitated proteins were detected by immunoblotting, and the activity
measured as the increase in histone H1 kinase activity of PY15 com-
pared with preimmune control precipitates. A and C represent averages
and standard deviation of triplicate determinations. In B and D, cdc25
immunoprecipitates from identical samples were incubated either with-
out or with l-phosphatase (1l), and the activities represent the mean
of duplicate determinations.
FIG. 7. Cdc25B and cdc25C are hyperphosphorylated at differ-
ent times during the cell cycle. HeLa cells were synchronized in
early S phase with a double thymidine block/release, and progression
through the cell cycle was monitored by flow cytometric analysis of the
DNA content of the cells after release from the second thymidine block.
The activation of cyclin B1/cdc2 was monitored by cyclin B1 immuno-
precipitate histone H1 kinase assays, and samples were immunblotted
with anti-cdc25B and anti-cdc25C antibodies.
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contribute to the increased catalytic rates for cyclin B1/cdc2
observed. In the case of cdc25B2 and cdc25B3, increased sub-
strate binding could completely account for the increased ac-
tivity, whereas it would appear that increased substrate bind-
ing may only partially account for the increased cdc25C activity
(Table II), the remainder perhaps due an increase in its intrin-
sic catalytic rate. The increased activity of the hyperphospho-
rylated forms of cdc25B and cdc25C immunoprecipitated from
mitotic HeLa cells compared with the underphosphorylated
forms from S/G2 cells was comparable with the increase ob-
tained with in vitro hyperphosphorylation. In the case of
cdc25C, the increased activity was due solely to the effects of
phosphorylation, in agreement with observations by others (10,
11). However, the inability of l-phosphatase to reduce the
activity of hyperphosphorylated cdc25B to S/G2 levels despite
the apparently complete dephosphorylation of the immunopre-
cipitated cdc25B suggests that other modifications might also
contribute to its mitotic activation in vivo.
The chimeric cdc25s have provided insight into the mecha-
nism by which the N-terminal domains may regulate the ac-
tivity of the cdc25s. The exchange of similarly sized N-terminal
domains which have little sequence similarity has resulted in
chimeric cdc25s with catalytic properties unlike either of the
parent proteins. The lack of effect of mitotic hyperphosphoryl-
ation on the activity of chimeras compared with the parent
cdc25s suggests that the chimeric N-terminal and C-terminal
domains are not in productive communication. The chimeras
do, however, provide evidence that the N-terminal domains
regulate cdc25 activity by restricting the access of substrates to
the C-terminal catalytic site. For example, GST-cdc25BC2 has
essentially no activity with any substrate, including the low
molecular weight p-nitrophenyl phosphate, whereas the full-
length cdc25C and the C-terminal fragment constructs are
capable of utilizing this substrate, suggesting that the chimeric
cdc25B3 N-terminal region reduces the access to the catalytic
site in the C-terminal of the chimera, which has intrinsic p-
nitrophenylphosphatase activity. The opposite is the case for
the cdc25CB3 chimera, which has similar activity to the cdc25B
C-terminal fragment construct with all the substrates tested in
this study (Table II). This suggests that the chimeric cdc25C
N-terminal region allows unimpeded access of substrates to the
catalytic pocket of the cdc25B C-terminal domain, equalling the
access permitted by the C-terminal cdc25B construct.
The chimeric cdc25s also confirm that the major mitotic
phosphorylation sites in cdc25B3 and cdc25C are located in the
chimeric N-terminal regions. Cdc25CB3 contains all of the
major mitotic phosphorylation sites identified in cdc25C (22),
but excludes the Ser216 site phosphorylated by a cdc25C-asso-
ciated kinase (23), and cdc25CB3 has a similar decrease in its
electrophoretic mobility as cdc25C after phosphorylation in
mitotic extracts. The major mitotic sites also appear to be
contained within the cdc25B3 N-terminal (1–251) region, indi-
cated by the similar electrophoretic shifts of cdc25B3 and
cdc25BC2 with mitotic phosphorylation.
Thus, one role for the relatively nonconserved N-terminal
domain of the cdc25s may control the access of substrates to the
catalytic C-terminal domain. The way in which the mitotic
phosphorylations of the N-terminal domains increase cdc25
activity toward cyclin/cdks is most likely through phosphoryl-
ation-induced alterations to the tertiary structure of the pro-
teins. In the parent cdc25s, the phosphorylation and resultant
structural changes in the N-terminal region may open up the
catalytic pocket to allow freer access for the substrates. How-
ever, we cannot exclude the possibility that phosphorylation
may also increase the affinity of the cdc25s for the substrates,
or increase the intrinsic catalytic rate. This may be particularly
relevant for cdc25C, as the cdc25C C-terminal fragment con-
struct was essentially inactive toward the cyclin/cdk sub-
strates, in contrast to the equivalent cdc25B construct.
The surprising result that the dramatic increases in binding
and catalytic activities with cyclin B1/cdc2 induced by hyper-
phosphorylation of the GST-cdc25s were not reflected in the
binding or activity with cyclin A/cdk2, with the exception of
GST-cdc25B3, which showed small increases in both binding
and activity for this complex, suggests that interaction of cyclin
B1/cdc2 and cyclin A/cdk2 with the cdc25s is very different, and
that the conformational changes induced by hyperphosphoryl-
ation of the N-terminal domain affects cyclin A/cdk2 access/
affinity to the catalytic site only minimally. The reason for this
lack of phosphorylation-dependent effect with cyclin A/cdk2
may be due to structural differences between the cyclin A and
cyclin B1-cdk complexes and the manner in which these com-
plexes interact with the cdc25s. The cdks have a high degree of
sequence identity, whereas, outside a few conserved domains,
cyclins are quite divergent and are likely to possess very dif-
ferent tertiary structures. Structural differences are also sug-
gested by the range of binding affinities of the cdk inhibitor
proteins, e.g. p21CIP1 and p27Kip1, for cyclin A and cyclin
B-cdk complexes (24).
Cell cycle analysis of expression of cdc25B and cdc25C shows
the expected dramatic increase in cdc25B proteins (cdc25B3 is
the most abundant form, although cdc25B2 expression is also
increased in G2)
2 as cells enter G2. Interestingly, the hyper-
phosphorylated forms of cdc25B start to appear at 8 h after
release from the thymidine block, prior to the activation of
cyclin B1/cdc2. The appearance of the hyperphosphorylated
cdc25C coincides with the activation of cyclin B1/cdc2 as has
been reported for cdc25 in yeast and Xenopus (2–4), and sup-
ports the autoamplification model for cdc25C activation by
cyclin B1/cdc2 (10). The low proportion of cdc25C in the hyper-
phosphorylated form in cells transiting mitosis suggests that
either the hyperphosphorylated form is a very transient spe-
cies, or that only a small proportion of cdc25C is required in
its activated form in mitosis. It is at present unclear as to
which of these possibilities represents the true physiological
situation, although the hyperphosphorylation of the total pool
of cdc25C has only been found in cells blocked in mitosis with
nocodazole (8).
The specificity and timing of activation of cdc25B and cdc25C
has interesting implications for their function in vivo. The
abrupt increase in cdc25B levels in G2 occurs prior to the
activation of a peak of cyclin A/cdk2 in that phase of the cell
cycle (25). At this time, cdc25B2 and cdc25B3 are localized to
the nucleus where the cyclin A/cdk2 is also localized (25), and
TABLE II
Relative activity of GST-cdc25s towards different substrates
Relative activity of the GST-cdc25s is expressed relative to the activ-
ity of GST-cdc25C. The activity of each GST-cdc25 with cyclin A/cdk2
and cyclin B1/cdc2 is the activity at 1 mol cdc25 from Fig. 2B. Fold
activation refers to the fold increase in activity with cyclin B1/cdc2 at 1
mol of each hyperphosphorylated GST-cdc25 from Fig. 3B. Cdc2 binding
refers to the fold increase in cdc2 associated with the hyperphospho-
rylated GST-cdc25 C/S mutants in Fig. 4.
pNPPa CyclinA/cdk2
Cyclin
B1/cdc2
-Fold
activation
Cdc2
binding
Cdc25B2 2.4 10 22 2 2–4
Cdc25B3 3 5 18 3.5 5–10
Cdc25C 1 1 3 15 5–10
Cdc25BC2 1 2 1
Cdc25CB3 9.5 13 75 1–2
Cdc25B C-terminal 14 10 80
Cdc25C C-terminal 1 1 2
a pNPP, p-nitrophenylphosphate.
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the in vitro substrate specificity experiments indicate that cy-
clin A/cdk2 is a good substrate for both cdc25Bs. Thus cdc25B2
and cdc25B3 may first activate cyclin A/cdk2 in G2, then
cdc25B3 accumulates in the cytoplasm where it activates part
of the pool of cyclin B1/cdc2, which in turn catalyzes changes in
microtubule dynamics and increased levels of microtubule nu-
cleation at the centrosome, both of which are blocked by over-
expressing catalytically inactive mutants of cdc25B3 (9). The
translocation of cyclin B1/cdc2 from the cytoplasm to the nu-
cleus in prophase is correlated with the conversion of the cen-
trosomes to mitotic microtubule organizing centers (26), and
thus translocation of cyclin B1/cdc2 must occur after cdc25B3
appears in the cytoplasm. It is unclear as to what proportion of
the cyclin B1/cdc2 pool is active when it is translocated, but
cdc25C may be hyperphosphorylated by the active cyclin B1/
cdc2 translocated into the nucleus, and the former may in turn
activate the remainder of the translocated pool of cyclin B1/
cdc2. The hyperphosphorylated cdc25C may also act on other,
unidentified substrates, but appears not have a role in the
activation cyclin A/cdk2.
In summary, we have shown that recombinant cdc25B2 and
cdc25B3 have relatively high activity toward Tyr15-phosphoryl-
ated cdc2/cyclin B1 and cdk2/cyclin A, with cdc25B2 having a
higher activity with cdk2/cyclin A than cdc25B3. Cdc25C pos-
sesses only very low or no activity with these substrates in
vitro. The hyperphosphorylated forms of these proteins all
showed increased activity with cdc2/cyclin B1, but little in-
crease in activity with cdk2/cyclin A. This was reflected in the
relative binding efficiencies of the cdc25s for the cdk-cyclin
complexes. Similar phosphorylation-dependent increases in
cdc25 activity where observed for cdc25B and cdc25C in vivo.
These data indicate that the different cdc25s potentially regu-
late different pools of cdk/cyclins, and suggest that the phos-
phorylation dependent activation of the cdc25s is due to con-
formational changes which result in increased access to the
catalytic pocket for the substrates.
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